With reports of Omicron cases in over 50 countries, and at least 19 US states, some regions like the UK are now expecting a rapid rise of Omicron as community spread takes off. While the UK has only…
Angion’s lead organ damage drug took two strikes earlier this year, flopping as a repurposed effort for Covid-19 and whiffing in high-risk kidney transplant patients. The biotech reported a third on…
Moderna is set to make tens of billions of dollars this year and next from its mRNA COVID vaccine and booster, but the market won’t let the Big Biotech rest on its laurels and wants broader…
Eli Lilly is making a $1.5 billion biobucks bet on Chinese biotech Regor Therapeutics to seek out, develop and hopefully sell new therapies for metabolic disorders.
A Stanford team discovered that a protein called clusterin is prevalent in exercising mice and prompts anti-inflammatory, brain-boosting effects. They concluded that a drug that reduces inflammation…
Novartis has been busy selling off its stake in Roche but quietly this month also got a little extra from its fellow Swiss native after nabbing Bob Baloh, M.D., Ph.D., to run its growing neuroscience…
Former FDA head Stephen Hahn is adding a new title to his role at Flagship Pioneering: CEO of the incubator’s blood cancer test startup Harbinger Health. Takeda’s oncology leader Rachael Brake heads…
Moderna taps Carnegie Mellon for in-house AI training academy
chale
Fri, 12/10/2021 – 10:30
When it put down a casual $43 billion to merge with Covidien in 2015, Medtronic inherited its Irish partner’s Dublin headquarters and wide range of medical devices—and, consequently, any and all of…
The disgraced Theranos founder’s legal team wrapped up the proceedings following Holmes’ more than 25 hours of questioning.
